EGFR and gastric cancer: In contrast, Maron et al. showed, in a small cohort, that there was no difference in survival between patients who exhibited EGFR amplification (by ctDNA NGS) compared to those non-amplified in patients not exposed to EGFR inhibitor therapy, demonstrating that EGFR amplification may not be prognostic in GC [36].